Outcomes of Intralesional Interferon-α2B for the Treatment of Peyronie Disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: We evaluated the efficacy of intralesional interferon-α2b for Peyronie disease, reviewed the impact of the timing of therapy from disease onset and identified variables predictive of a response. MATERIALS AND METHODS: We retrospectively reviewed the charts of patients treated with intralesional interferon-α2b from 2001 to 2012. Demographic information, disease characteristics, pretreatment and posttreatment penile duplex ultrasound findings, and objective measures were analyzed. Response was defined as a 20% or greater improvement in curvature. Statistical analysis was done to identify significant changes in variables and identify predictive factors. RESULTS: A total of 127 patients with a mean age of 55 years (range 25 to 76) and a mean±SD pretreatment curvature of 42.4±18.6 degrees underwent a median of 12 biweekly interferon-α2b injections (range 6 to 24). The median history of Peyronie disease was 2.0 years (range 0.5 to 23). Of the patients 54% responded to therapy with an overall mean improvement of 9.0 degrees (p<0.001). Patients with less than 30-degree curvature were most likely to experience a 20% or greater improvement with interferon-α2b (86% response, p<0.001). However, similar overall improvement in pretreatment curvature was noted in all cases. No statistically significant improvement was observed in penile vascular status or ultrasound parameters. The duration of Peyronie disease did not impact the change in curvature. Age, pretreatment curvature, vascular status, penile ultrasound findings, curvature site and International Index of Erectile Function (IIEF) score did not predict the response to therapy. CONCLUSIONS: Intralesional therapy with interferon-α2b resulted in significantly improved curvature without impacting penile vascular parameters. The absolute improvement in curvature was independent of pretreatment curvature or Peyronie disease duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelbard, M., Goldstein, I., Hellstrom, W. J. G., McMahon, C. G., Smith, T., Tursi, J., Jones, N., Kaufman, G. J., & Carson, C. C. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.01.087 · Cited by 466
Self-citationEAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309
Hellstrom, W. J. G., Kendirci, M., Matern, R., Cockerham, Y., Myers, L., Sikka, S. C., Venable, D., Honig, S., McCullough, A., Hakim, L. S., et al. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00517-9 · Cited by 223
Self-citation
Cited by
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
Bella, A. J., Lee, J. C., Grober, E. D., Carrier, S., Benard, F., & Brock, G. B. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5255 · Cited by 68
Nonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Review of Management Options for Patients With Atypical Peyronie's Disease
Yafi, F. A., Hatzichristodoulou, G., DeLay, K. J., & Hellstrom, W. J. G. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2016.07.004 · Cited by 38
Self-citationPeyronie’s disease: pharmacological treatments and limitations
Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1903873 · Cited by 24
Metadata
- Authors
- Trost, L. W., Ates, E., Powers, M., Sikka, S., & Hellstrom, W. J. G.
- Venue
- Journal of Urology
- Published
- 2013-12
- Volume
- 190
- Issue
- 6
- Pages
- 2194-2199
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2035600000
- Cited by
- 50
- References
- 3
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.